Financial Ratios

ZYDUS LIFESCIENCES LTD.

NSE : ZYDUSLIFEBSE : 532321ISIN CODE : INE010B01027Industry : Pharmaceuticals & DrugsHouse : Cadila
BSE1005.255.65 (+0.57 %)
PREV CLOSE ( ) 999.60
OPEN PRICE ( ) 998.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 56587
TODAY'S LOW / HIGH ( )987.00 1020.95
52 WK LOW / HIGH ( )482.55 1030.15
NSE1007.357.65 (+0.77 %)
PREV CLOSE( ) 999.70
OPEN PRICE ( ) 993.00
BID PRICE (QTY) 1007.35 (18)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1873843
TODAY'S LOW / HIGH( ) 985.00 1021.00
52 WK LOW / HIGH ( )483.5 1027.8
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)15.118.3814.4213.2214.06
   CEPS(Rs)19.9413.0518.8217.4117.56
   DPS(Rs)6.002.503.503.503.50
   Book NAV/Share(Rs)134.78129.30124.46109.9683.68
   Tax Rate(%)24.7526.2912.5713.1017.31
Margin Ratios
   Core EBITDA Margin(%)24.9822.5729.5622.3726.91
   EBIT Margin(%)26.4916.5522.5428.2330.36
   Pre Tax Margin(%)23.3014.8321.6324.5428.84
   PAT Margin (%)17.5310.9318.9121.3323.85
   Cash Profit Margin (%)23.1317.0324.6928.0829.78
Performance Ratios
   ROA(%)7.114.297.728.1510.17
   ROE(%)11.386.6012.3013.6517.65
   ROCE(%)13.457.9811.1313.2216.10
   Asset Turnover(x)0.410.390.410.380.43
   Sales/Fixed Asset(x)1.111.071.151.001.13
   Working Capital/Sales(x)2.002.796.454.724.15
Efficiency Ratios
   Fixed Capital/Sales(x)0.900.940.871.000.88
   Receivable days121.0097.23101.96131.36101.78
   Inventory Days77.6086.1874.2382.4484.43
   Payable days148.14162.08182.09172.30177.24
Valuation Parameters
   PER(x)32.5341.6230.5820.2124.65
   PCE(x)24.6526.7123.4215.3419.74
   Price/Book(x)3.652.703.542.434.14
   Yield(%)1.220.720.791.311.01
   EV/Net Sales(x)6.224.866.294.836.45
   EV/Core EBITDA(x)18.0918.1520.3913.4917.78
   EV/EBIT(x)23.5129.3127.8017.1121.26
   EV/CE(x)2.351.912.431.692.58
   M Cap / Sales5.704.565.804.315.88
Growth Ratio
   Net Sales Growth(%)11.420.7322.575.133.92
   Core EBITDA Growth(%)43.21-12.565.523.7118.17
   EBIT Growth(%)77.89-26.18-1.80-2.2617.42
   PAT Growth(%)78.25-41.889.06-5.9931.99
   EPS Growth(%)80.36-41.889.06-5.9931.99
Financial Stability Ratios
   Total Debt/Equity(x)0.350.200.310.330.42
   Current Ratio(x)2.081.571.231.341.47
   Quick Ratio(x)1.641.180.890.990.99
   Interest Cover(x)8.309.6324.827.6619.99
   Total Debt/Mcap(x)0.100.070.090.140.10

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.